Nonengraftment Haploidentical Cellular Therapy for Hematologic Malignancies
Much of the therapeutic benefit of allogeneic transplant is by a graft versus tumor effect. Further data shows that transplant engraftment is not dependant on myeloablation, instead relying on quantitative competition between donor and host cells. In the clinical setting, engraftment by competition...
Saved in:
| Main Authors: | John L. Reagan, Loren D. Fast, Eric S. Winer, Howard Safran, James N. Butera, Peter J. Quesenberry |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2012-01-01
|
| Series: | Advances in Hematology |
| Online Access: | http://dx.doi.org/10.1155/2012/784213 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Optimizing Haploidentical Hematopoietic Stem Cell Transplantation: Enhancing Outcomes in Hematologic Malignancies in Resource-Limited Settings
by: Owattanapanich W, et al.
Published: (2025-03-01) -
Comparable Outcomes for Hematologic Malignancies after HLA-Haploidentical Transplantation with Posttransplantation Cyclophosphamide and HLA-Matched Transplantation
by: Shannon R. McCurdy, et al.
Published: (2015-01-01) -
Haploidentical Hematopoietic Stem Cell Transplantation: Expanding the Horizon for Hematologic Disorders
by: Mohammad Faizan Zahid, et al.
Published: (2016-01-01) -
Haploidentical Stem Cell Transplantation in Adult Haematological Malignancies
by: Kevon Parmesar, et al.
Published: (2016-01-01) -
Molecular-Targeted Therapies for Hematologic Malignancies
by: Kevin D. Bunting, et al.
Published: (2012-01-01)